全文获取类型
收费全文 | 1288328篇 |
免费 | 97079篇 |
国内免费 | 2978篇 |
专业分类
耳鼻咽喉 | 16526篇 |
儿科学 | 41328篇 |
妇产科学 | 35110篇 |
基础医学 | 191846篇 |
口腔科学 | 35270篇 |
临床医学 | 120500篇 |
内科学 | 251214篇 |
皮肤病学 | 27750篇 |
神经病学 | 103240篇 |
特种医学 | 47918篇 |
外国民族医学 | 270篇 |
外科学 | 182115篇 |
综合类 | 30022篇 |
现状与发展 | 7篇 |
一般理论 | 571篇 |
预防医学 | 106455篇 |
眼科学 | 28487篇 |
药学 | 94731篇 |
39篇 | |
中国医学 | 3241篇 |
肿瘤学 | 71745篇 |
出版年
2021年 | 10720篇 |
2019年 | 10842篇 |
2018年 | 14386篇 |
2017年 | 11221篇 |
2016年 | 12148篇 |
2015年 | 14254篇 |
2014年 | 19365篇 |
2013年 | 29035篇 |
2012年 | 39724篇 |
2011年 | 42118篇 |
2010年 | 24616篇 |
2009年 | 23552篇 |
2008年 | 39197篇 |
2007年 | 41795篇 |
2006年 | 41277篇 |
2005年 | 40211篇 |
2004年 | 38413篇 |
2003年 | 36835篇 |
2002年 | 35552篇 |
2001年 | 56473篇 |
2000年 | 57336篇 |
1999年 | 48289篇 |
1998年 | 13528篇 |
1997年 | 12332篇 |
1996年 | 12735篇 |
1995年 | 11994篇 |
1994年 | 11188篇 |
1992年 | 38252篇 |
1991年 | 37710篇 |
1990年 | 36475篇 |
1989年 | 35289篇 |
1988年 | 32719篇 |
1987年 | 32061篇 |
1986年 | 30565篇 |
1985年 | 28820篇 |
1984年 | 21966篇 |
1983年 | 19214篇 |
1982年 | 11386篇 |
1979年 | 20965篇 |
1978年 | 15402篇 |
1977年 | 12793篇 |
1976年 | 11853篇 |
1975年 | 12815篇 |
1974年 | 15592篇 |
1973年 | 15367篇 |
1972年 | 14517篇 |
1971年 | 13554篇 |
1970年 | 12787篇 |
1969年 | 12070篇 |
1968年 | 11235篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
21.
As millions of people turn to social media for health information, better understanding the factors that guide health-related judgments and perceptions in this context is imperative. We report on two Web experiments (n > 400 total) examining the power of society’s widespread weight bias and related stereotypes to influence nutrition judgments in social media spaces. In Experiment 1, meals were judged as lower in nutritional quality when the person who recommended them (the source) was depicted as obese rather than of normal weight, an effect mediated by stereotypic beliefs about the source as a generally unhealthy person. Experiment 2 replicated this effect, which—notably—remained significant when controlling for objective nutritional information (calories and fat content). Results highlight spillover effects of weight bias that extend beyond person perception to color impressions of objects (here, food) that are associated with stigmatized attributes. Implications for everyday nutrition judgments and public health are considered. 相似文献
22.
23.
24.
25.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献
26.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
27.
我国属胃癌高发国家,且以进展期胃癌为主。以手术和化疗为主的多学科治疗无法有效改善晚期胃癌患者的预后。近年来,免疫检查点抑制剂类药物的疗效在诸多癌症中得到了证实,因此,该类药物在胃癌中的治疗效果也受到了广泛的关注。本文对近年来的相关研究成果进行综述,全面介绍了免疫检查点抑制剂类药物在胃癌治疗中的临床应用情况、联合用药情况以及不良反应。对于其他治疗均失败的晚期胃癌患者,PD-1抑制剂是一个可行的治疗选项,其代表药物派姆单抗是目前唯一被美国食品药品监督管理局批准应用于胃癌治疗的免疫抑制剂类药物,而我国国家食品药品监督管理总局尚未批准任何此类药物应用于胃癌的临床治疗。如何进一步提高治疗的客观缓解率,将会是后续临床和基础研究的一大焦点。 相似文献
28.
Sundaram Kavin Piuzzi Nicolas S. Patterson Brendan M. Stearns Kim L. Krebs Viktor E. Mont Michael A. 《European journal of orthopaedic surgery & traumatology : orthopedie traumatologie》2020,30(3):447-453
European Journal of Orthopaedic Surgery & Traumatology - The goals of this study were to compare patient satisfaction and wound-related complications in patients receiving 2-octyl cyanoacrylate... 相似文献
29.
经济社会的快速发展,提升了人们的生活水平人们对医疗事业的发展提出了更高的要求,我国也加大了对医疗事业的建设与发展。尤其是所使用的相关设备与仪器。其中,医用B超就是最主要的医疗设备,能够通过设备的检查,对人体的身体情况以数据的形式展现,直接能够了解到人体的健康情况,提升医疗事业的技术水平,同时,也为医疗工作这提供了方便快捷的工作方式。但是,医用B超设备在使用的过程中,会受到一些因素的影响,使其发生故障,会对各项工作造成不同程度的影响。因此,需要对其加强管理,能够及时地发现故障问题,采取科学的措施解决,确保医疗事业的稳定发展。 相似文献